AR076694A1 - Benzoxazepinas como inhibidores de pi3k/m/tor, su uso en el tratamiento del cancer y su preparacion - Google Patents

Benzoxazepinas como inhibidores de pi3k/m/tor, su uso en el tratamiento del cancer y su preparacion

Info

Publication number
AR076694A1
AR076694A1 ARP100101771A ARP100101771A AR076694A1 AR 076694 A1 AR076694 A1 AR 076694A1 AR P100101771 A ARP100101771 A AR P100101771A AR P100101771 A ARP100101771 A AR P100101771A AR 076694 A1 AR076694 A1 AR 076694A1
Authority
AR
Argentina
Prior art keywords
optionally substituted
alkyl
hydroxyalkyl
haloalkyl
independently
Prior art date
Application number
ARP100101771A
Other languages
English (en)
Inventor
Tsze H Tsang
Charles M Blazey
Cristina A Zaharia
Owen Joseph Bowles
Amy L Tsuhako
Joerg Bussenius
Chris Allen Buhr
Jason R Harris
Angie Inyoung Kim
Anagha Joshi
Stephanie Ng
Csaba J Peto
Neel Kumar Anand
Kenneth D Rice
Steven Charles Defina
Larisa Dubenko
Sunghoon Ma
Jeffry Kimo Curtis
Eileen Jackson-Ugueto
Jean-Claire Limun Manalo
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of AR076694A1 publication Critical patent/AR076694A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Se preveen composiciones farmacéuticas que comprenden métodos para preparar y uso de los compuestos en el tratamiento del cáncer. Reivindicacion 1: Un compuesto de la formula 1: o uno de sus estereoisomeros individuales o una mezcla de estereoisomeros y además, opcionalmente como una de sus sales farmacéuticamente aceptables, en donde R1es fenilo opcionalmente sustituido con uno, dos o tres grupos R6 o R1 es heteroarilo opcionalmente sustituido con uno, dos o tres R7 R2 es heteroarilo sustituido con R3, R3a, R3b, R3c y R3d; R3, R3a, R3b, R3c y R3d son, de modo independiente, hidrogeno, ciano, alquilo, alquenilo, halo, haloalquilo, hidroxialquilo, alcoxialquilo, cianoalquilo, -SR12, -S(O) 2R20, -C(O)OR4, halocarbonilo, -NR11R11a, -OR11a fenilo opcionalmente sustituido, fenilalquilo opcionalmente sustituido, cicloalquilo opcionalmente sustituido, cicloalquilalquilo opcionalmente sustituido, heterocicloalquilo opcionalmente sustituido, heterocicloalquilalquilo opcionalmente sustituido, heteroarilo opcionalmente sustituido, heteroarilalquilo opcionalmente sustituido o alquilo sustituido con uno o dos R16 o dos de R3, R3a, R3b, R3c y R3d cuando se unen con el mismo carbono, forman un cicloalquilo opcionalmente sustituido o un heterocicloalquilo opcionalmente sustituido; y el otro de R3, R3a, R3b, R3c y R3d son, de modo independiente, hidrogeno, ciano, alquilo, alquenilo, halo, haloalquilo, hidroxialquilo, alcoxialquilo, cianoalquilo, -SR12, -S(O)2R20, -C(O)OR4, halocarbonilo, -NR11R11a, -OR11a, fenilo opcionalmente sustituido, fenilalquilo opcionalmente sustituido, cicloalquilo opcionalmente sustituido, cicloalquilalquilo opcionalmente sustituido, heterocicloalquilo opcionalmente sustituido, heterocicloalquilalquilo opcionalmente sustituido, heteroarilo opcionalmente, heteroarilalquilo opcionalmente sustituido o alquilo sustituido con uno o dos R16 R4 es alquilo, alquenilo, alquinilo, hidroxialquilo, alcoxialquilo, haloalquilo, bencilo o heterocicloalquilalquilo opcionalmente sustituido; R5a y R5c son, de modo independiente, hidrogeno o alquilo; R5h es hidrogeno o halo; R5b es hidrogeno, amino o halo; R5d, R5e, R5f y R5g son hidrogeno; cada R6, cuando R6 está presente, es, de modo independiente, nitro; ciano; halo; alquilo; alquenilo; alquinilo; haloalquilo; -OR8a; -NR8R8a; -C(O)NR8R8a; - S(O)2R8, -NR8C(O)OR9, -NR8C(O)R9, -NR8S(O)2R8a;. -NR8C(O)NR8aR9 carboxi, -C(O)OR9 halocarbonilo; alquilcarbonilo; alquilo sustituido con uno o dos -C(O)NR8R8a; heteroarilo opcionalmente sustituido con 1, 2 o 3 R14; o heterocicloalquilo opcionalmente sustituido; cada R7, cuando R7 está presente, es, de modo independiente, oxo; nitro; ciano; alquilo; alquenilo; alquinilo; halo; haloalquilo; hidroxialquilo; alcoxialquilo; -OR8a; -SR13 -S(O)R13a, -S(O)2R13a; -NR8R8a; -C(O)NR8R8a, -NR8C(O)OR9, -NR8C(O)R9; -NR8S(O)2R8a; -NR8C(O)NR8aR9, -C(O)OR9 halocarbonilo; alquilcarbonilo; -S(O)2NR8R9 alquilsulfonilalquilo; alquilo sustituido con uno o dos -NR8R8a; alquilo sustituido con uno o dos -NR8C(O)R8a; alquilo sustituido, con uno o dos -NR8C(O)OR9 alquilo sustituido con uno o dos -S(O)2R13a; cicloalquilo opcionalmente sustituido; cicloalquilalquilo opcionalmente sustituido; heterocicloalquilo opcionalmente sustituido; heterocicloalquilalquilo opcionalmente sustituido; fenilo opcionalmente sustituido; fenilalquilo opcionalmente sustituido; heteroarilo opcionalmente sustituido; o heteroarilalquilo opcionalmente sustituido; cada R8, R11, R15, R17 y R18 es, de modo independiente, hidrogeno, alquilo, alquenilo, alquinilo, hidroxialquilo, alcoxialquilo o haloalquilo; cada R8a, R11a , R15a es, de modo independiente, hidrogeno, alquilo, alquenilo, alquinilo, haloalquilo, hidroxialquilo, cianoalquilo, aminoalquilo, alquilaminoalquilo, dialquilaminoalquilo, alcoxialquilo, carboxialquilo, cicloalquilo opcionalmente sustituido, cicloalquilalquilo opcionalmente sustituido, heterocicloalquilo opcionalmente sustituido, heterocicloalquilalquilo opcionalmente sustituido, fenilo opcionalmente sustituido, fenilalquilo opcionalmente sustituido, heteroarilo opcionalmente sustituido o heteroarilalquilo opcionalmente sustituido; R9 es hidrogeno; alquilo; alquenilo; alquinilo; hidroxialquilo; alcoxialquilo; aminoalquilo; alquilaminoalquilo; dialquilaminoalquilo; haloalquilo; hidroxialquilo sustituido con uno, dos o tres grupos que son, de modo independiente, halo, amino, alquilamino o dialquilamino; alquilo sustituido con uno o dos aminocarbonilo; fenilo opcionalmente sustituido; fenilalquilo opcionalmente sustituido; cicloalquilo opcionalmente sustituido; cicloalquilalquilo opcionalmente sustituido; heteroarilo opcionalmente sustituido; heteroarilalquilo opcionalmente sustituido; heterocicloalquilo opcionalmente sustituido; o heterocicloalquilalquilo opcionalmente sustituido; R12 es alquilo o fenilalquilo opcionalmente sustituido; R13 es alquilo, hidroxialquilo o haloalquilo; y R13a es hidroxi, alquilo, haloalquilo, hidroxialquilo o heterocicloalquilo opcionalmente sustituido con uno o dos grupos que son, de modo independiente, halo, amino, alquilamino, dialquilamino, hidroxi, alquilo o hidroxialquilo; cada R14, cuando R14 está presente, es, de modo independiente, amino, alquilamino, dialquilamino, acilamino, halo, hidroxi, alquilo, haloalquilo, hidroxialquilo, aminoalquilo, alquilaminoalquilo, dialquilaminoalquilo, alcoxicarbonilo, aminocarbonilo, alquilaminocarbonilo, dialquilaminocarbonilo o fenilo opcionalmente sustituido; cada R16 es, de modo independiente, -NR11R12a, -NR15S(O)R15a, -OC(O)R17 u -OR18 y R20 es alquilo, haloalquilo, hidroxialquilo, amino, alquilamino, dialquilamino o heterocicloalquilo.
ARP100101771A 2009-05-22 2010-05-21 Benzoxazepinas como inhibidores de pi3k/m/tor, su uso en el tratamiento del cancer y su preparacion AR076694A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21698009P 2009-05-22 2009-05-22

Publications (1)

Publication Number Publication Date
AR076694A1 true AR076694A1 (es) 2011-06-29

Family

ID=42556812

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100101771A AR076694A1 (es) 2009-05-22 2010-05-21 Benzoxazepinas como inhibidores de pi3k/m/tor, su uso en el tratamiento del cancer y su preparacion

Country Status (13)

Country Link
US (1) US8648066B2 (es)
EP (1) EP2432779A1 (es)
JP (1) JP2012527474A (es)
KR (1) KR20120034666A (es)
CN (1) CN102459249A (es)
AR (1) AR076694A1 (es)
AU (1) AU2010249790A1 (es)
BR (1) BRPI1010974A2 (es)
CA (1) CA2763099A1 (es)
IL (1) IL216472A0 (es)
MX (1) MX2011012345A (es)
TW (1) TW201111371A (es)
WO (1) WO2010135524A1 (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
NZ587051A (en) 2008-01-04 2012-12-21 Intellikine Llc Isoquinolinone derivatives, compositions and methods of inhibiting phosphatidyl inositol-3 kinase (pi3 kinase)
CN102459248A (zh) 2009-05-26 2012-05-16 埃克塞里艾克西斯公司 作为PI3K/mTOR抑制剂的苯并氧杂环庚三烯以及它们使用与制造方法
EP2445902A2 (en) * 2009-06-25 2012-05-02 Amgen, Inc Heterocyclic compounds and their uses as inhibitors of pi3k activity
WO2012037204A1 (en) 2010-09-14 2012-03-22 Exelixis, Inc. Inhibitors of pi3k-delta and methods of their use and manufacture
EP2624696B1 (en) 2010-10-06 2016-12-21 Glaxosmithkline LLC Benzimidazole derivatives as pi3 kinase inhibitors
DE102010049595A1 (de) * 2010-10-26 2012-04-26 Merck Patent Gmbh Chinazolinderivate
EP2640367A2 (en) * 2010-11-15 2013-09-25 Exelixis, Inc. Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
WO2012068096A2 (en) * 2010-11-15 2012-05-24 Exelixis, Inc. Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
CN103402999A (zh) * 2010-11-24 2013-11-20 埃克塞里艾克西斯公司 作为PI3K/mTOR抑制剂的苯并氧氮杂卓及其使用和生产方法
BR112013012961A2 (pt) * 2010-11-24 2019-09-24 Exelixis Inc benzoxazepinas como inhibidores de mtor e métodos de seu uso e fabricação
EP2643315A1 (en) * 2010-11-24 2013-10-02 Exelixis, Inc. BENZOXAZEPINES AS INHIBITORS OF P13K/mTOR AND METHODS OF THEIR USE AND MANUFACTURE
CN103459384A (zh) * 2010-11-24 2013-12-18 埃克塞里艾克西斯公司 作为PI3K/mTOR抑制剂的苯并氧氮杂环庚三烯以及它们使用和制造方法
CN103648499B (zh) 2011-01-10 2017-02-15 无限药品股份有限公司 用于制备异喹啉酮的方法及异喹啉酮的固体形式
BR112013024122A2 (pt) * 2011-03-21 2019-09-24 Hoffmann La Roche compostos de benzoxazepina seletivos para p110 delta pi3k e métodos de uso
WO2012149540A1 (en) * 2011-04-28 2012-11-01 The Broad Institute Inc Inhibitors of histone deacetylase
CN103732588B (zh) * 2011-07-27 2016-10-12 南京奥昭生物科技有限公司 螺环分子作为蛋白激酶抑制剂
CN107375289A (zh) 2011-11-01 2017-11-24 埃克塞利希斯股份有限公司 用于治疗淋巴组织增生性恶性肿瘤的作为磷脂酰肌醇3‑激酶抑制剂的化合物
JP5949070B2 (ja) * 2012-04-03 2016-07-06 Jsr株式会社 液晶配向剤、液晶配向膜及び液晶表示素子
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
MA37756B1 (fr) 2012-06-13 2018-09-28 Hoffmann La Roche Nouveaux composés diazaspirocycloalcane et azaspirocycloalcane
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
EP2877444B1 (en) 2012-07-27 2020-09-02 The Broad Institute, Inc. Inhibitors of histone deacetylase
EP3590940B1 (en) 2012-09-25 2021-06-09 F. Hoffmann-La Roche AG Hexahydropyrrolo[3,4-c]pyrrole derivatives and related compounds as autotaxin (atx) inhibitors and as inhibitors of the lysophosphatidic acid (lpa) production for treating e.g. renal diseases
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
MA38982A1 (fr) 2013-11-26 2017-09-29 Hoffmann La Roche Nouvel octahydro-cyclobuta [1,2-c; 3,4-c'] dipyrrol-2-yl
WO2015108861A1 (en) 2014-01-14 2015-07-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
EP3094326A4 (en) 2014-01-14 2017-07-26 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
CN106103446B (zh) 2014-03-26 2019-07-30 豪夫迈·罗氏有限公司 作为自分泌运动因子(atx)和溶血磷脂酸(lpa)生产抑制剂的二环化合物
MX2016010675A (es) 2014-03-26 2016-11-10 Hoffmann La Roche Compuestos condensados de [1,4]diazepina como inhibidores de produccion de la autotaxina (atx) y acido lisofosfatidico (lpa).
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
MA41898A (fr) 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
CN104910158B (zh) * 2015-06-15 2017-04-12 河南师范大学 具有生物活性的5,6,7,8‑四氢吡啶并[3,4‑d]嘧啶化合物及其制备方法和应用
CN108026077B (zh) 2015-09-04 2021-11-05 豪夫迈·罗氏有限公司 苯氧基甲基衍生物
MA42918A (fr) 2015-09-24 2018-08-01 Hoffmann La Roche Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
JP6845230B2 (ja) 2015-09-24 2021-03-17 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ デュアルａｔｘ／ｃａ阻害剤としての新規な二環式化合物
MA42923A (fr) 2015-09-24 2021-04-28 Hoffmann La Roche Composés bicycliques comme inhibiteurs mixtes de atx/ca
WO2017050792A1 (en) 2015-09-24 2017-03-30 F. Hoffmann-La Roche Ag Bicyclic compounds as atx inhibitors
WO2017223422A1 (en) 2016-06-24 2017-12-28 Infinity Pharmaceuticals, Inc. Combination therapies
CN110114361B (zh) * 2016-12-15 2022-04-12 葛兰素史密斯克莱知识产权发展有限公司 Nrf2化合物
CN110382484B (zh) 2017-03-16 2022-12-06 豪夫迈·罗氏有限公司 新的作为atx抑制剂的二环化合物
MA49879A (fr) 2017-03-16 2020-06-24 Hoffmann La Roche Composés hétérocycliques utiles en tant qu'inhibiteurs doubles d'atx/ca
CN109311897B (zh) 2017-03-20 2021-07-20 福马治疗股份有限公司 作为丙酮酸激酶(pkr)活化剂的吡咯并吡咯组合物
US20200129485A1 (en) 2018-09-19 2020-04-30 Forma Therapeutics, Inc. Treating sickle cell disease with a pyruvate kinase r activating compound
US20230055923A1 (en) 2018-09-19 2023-02-23 Forma Therapeutics, Inc. Activating pyruvate kinase r
MX2022001863A (es) 2019-08-12 2022-05-30 Deciphera Pharmaceuticals Llc Metodos para tratar los tumores del estroma gastrointestinal.
WO2021030405A1 (en) 2019-08-12 2021-02-18 Deciphera Pharmaceuticals, Llc Ripretinib for treating gastrointestinal stromal tumors
RS65058B1 (sr) 2019-12-30 2024-02-29 Deciphera Pharmaceuticals Llc Formulacije inhibitora amorfne kinaze i postupci njihove primene
BR112022013169A2 (pt) 2019-12-30 2022-09-13 Deciphera Pharmaceuticals Llc Composições de 1-(4-bromo-5-(1-etil-7-(metilamino)-2-oxo-1,2-diidro-1,6-naftiridin-3-il)-2-fluorofeil)-3-fenilurea
WO2021204589A1 (en) 2020-04-07 2021-10-14 Bayer Aktiengesellschaft Substituted thiazolopyridines, salts thereof and their use as herbicidally active substances
TW202328150A (zh) 2021-09-07 2023-07-16 德商拜耳廠股份有限公司 經取代之噻唑并吡啶、其鹽及其作為除草活性物質之用途
TW202328151A (zh) 2021-09-07 2023-07-16 德商拜耳廠股份有限公司 經取代之2,3-二氫[1,3]噻唑并[4,5-b]吡啶、其鹽及其作為除草活性物質之用途
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4102103A1 (de) * 1991-01-25 1992-08-20 Bayer Ag Substituierte benzoxazepine und benzthiazepine, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
US5272158A (en) 1991-10-29 1993-12-21 Merck & Co., Inc. Fibrinogen receptor antagonists
WO1997024124A1 (en) 1995-12-29 1997-07-10 Smithkline Beecham Corporation Vitronectin receptor antagonists
AU1353897A (en) 1995-12-29 1997-07-28 Smithkline Beecham Corporation Vitronectin receptor antagonists
SE9701681D0 (sv) * 1997-05-05 1997-05-05 Astra Ab New compounds
WO2000046215A1 (en) 1999-02-03 2000-08-10 Merck & Co., Inc. Benzazepine derivatives as alpha-v integrin receptor antagonists
BR0013610A (pt) 1999-08-27 2002-07-16 Procter & Gamble Componentes de formulções de ação rápida,composições e métodos para lavar roupa empregando os mesmos
AU6935800A (en) 1999-08-27 2001-03-26 Procter & Gamble Company, The Controlled availability of formulation components, compositions and laundry methods employing same
ATE311432T1 (de) 1999-08-27 2005-12-15 Procter & Gamble Stabile substanzen, zusammensetzungen und waschverfahren zu deren verwendung
CN1384867A (zh) 1999-08-27 2002-12-11 宝洁公司 稳定性提高的配制组分、使用该组分的组合物和洗衣方法
US6723752B2 (en) * 1999-09-23 2004-04-20 Pharmacia Corporation (R)-chiral halogenated substituted n-benzyl-n-phenyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity
US20030114448A1 (en) 2001-05-31 2003-06-19 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
US7524883B2 (en) 2002-01-08 2009-04-28 Eisai R&D Management Co., Ltd. Eponemycin and epoxomicin analogs and uses thereof
US7196108B2 (en) 2002-03-08 2007-03-27 Incyte San Diego Inc. Bicyclic heterocycles for the treatment of diabetes and other diseases
CL2004000409A1 (es) 2003-03-03 2005-01-07 Vertex Pharma Compuestos derivados de 2-(cilo sustituido)-1-(amino u oxi sustituido)-quinazolina, inhibidores de canales ionicos de sodio y calcio dependientes de voltaje; composicion farmaceutica; y uso del compuesto en el tratamiento de dolor agudo, cronico, neu
US7521457B2 (en) * 2004-08-20 2009-04-21 Boehringer Ingelheim International Gmbh Pyrimidines as PLK inhibitors
DK1881823T3 (en) 2005-05-17 2015-03-02 Sarcode Bioscience Inc COMPOSITION AND PROCEDURES FOR TREATMENT OF EYE DISORDERS
WO2007004960A1 (en) * 2005-07-05 2007-01-11 Astrazeneca Ab New compounds, process for their preparation, intermediates, pharmaceutical compositions and their use in the treatment of 5-ht6 mediated disorders such as alzheimer’s desease, cognitive disorders, cognitive impairment associated with schizophrenia, obesity and parkinson’s disease
WO2008109599A1 (en) * 2007-03-05 2008-09-12 Wyeth Pyrimido [5,4-c] quinoline-2, 4-diamine derivatives and methods of use thereof
EP2125816A2 (en) * 2007-03-07 2009-12-02 Alantos Pharmaceuticals Holding, Inc. Metalloprotease inhibitors containing a heterocyclic moiety
JP5497429B2 (ja) * 2007-03-07 2014-05-21 武田薬品工業株式会社 ベンゾオキサゼピン誘導体およびその用途
WO2008144483A2 (en) 2007-05-18 2008-11-27 Armgo Pharma, Inc. Agents for treating disorders involving modulation of ryanodine receptors
WO2009026444A1 (en) 2007-08-22 2009-02-26 President And Fellows Of Harvard College Ryanodine channel binders and uses thereof
WO2009042092A1 (en) * 2007-09-25 2009-04-02 Merck & Co., Inc. 2-aryl or heteroaryl indole derivatives
WO2009076631A1 (en) 2007-12-12 2009-06-18 Rigel Pharmaceuticals, Inc. Carboxamide, sulfonamide and amine compounds for metabolic disorders
CN101497612A (zh) 2009-03-03 2009-08-05 北京华禧联合科技发展有限公司 一类新喹诺酮类化合物及其制备与用途
CN102459248A (zh) * 2009-05-26 2012-05-16 埃克塞里艾克西斯公司 作为PI3K/mTOR抑制剂的苯并氧杂环庚三烯以及它们使用与制造方法

Also Published As

Publication number Publication date
CA2763099A1 (en) 2010-11-25
US20100298290A1 (en) 2010-11-25
JP2012527474A (ja) 2012-11-08
US8648066B2 (en) 2014-02-11
WO2010135524A8 (en) 2012-01-12
MX2011012345A (es) 2012-01-31
TW201111371A (en) 2011-04-01
EP2432779A1 (en) 2012-03-28
IL216472A0 (en) 2012-01-31
KR20120034666A (ko) 2012-04-12
AU2010249790A1 (en) 2011-12-08
BRPI1010974A2 (pt) 2019-09-24
CN102459249A (zh) 2012-05-16
WO2010135524A1 (en) 2010-11-25

Similar Documents

Publication Publication Date Title
AR076694A1 (es) Benzoxazepinas como inhibidores de pi3k/m/tor, su uso en el tratamiento del cancer y su preparacion
AR076271A1 (es) Inhibidores de mtor, composiciones farmaceuticas, metodo de fabricacion y su uso en el tratamiento de cancer
AR076922A1 (es) Benzodiazepinas como inhibidores de pi3k/mtor, una composicion farmaceutica que las comprende, metodos para su fabricacion y su uso en el tratamiento del cancer.
AR083199A1 (es) Compuestos de n-heteroarilo con unidad de puente ciclico
AR084849A1 (es) Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos
AR092108A1 (es) Piridazina 1,4 disustituida, analogos de la misma y metodos para tratar las enfermedades relacionadas con deficiencia del smn
NI201400023A (es) Derivados de pirrolopirimidina y purina
AR077328A1 (es) Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos
AR080865A1 (es) Derivados de espirotetrahidronaftaleno, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos para tratar enfermedades neurodegenerativas,tal como alzheimer.
CR20140091A (es) Nuevos derivados dihidroquinolina-2-ona
AR072906A1 (es) Nucleosidos modificados utiles como antivirales
AR063912A1 (es) Derivados de 1,2,4 oxadiazol. composiciones farmaceuticas.
CO6140024A2 (es) Uso de compuestos inhibidores de quinaxolina de pi3k-alfa para el tratamiento del cancer
AR076435A1 (es) Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos
AR067757A1 (es) Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales.
AR081390A1 (es) Compuestos de morfolina, composiciones farmaceuticas que los comprenden y su uso en el tratamiento de enfermedades mediadas por el antagonismo del receptor mineralocorticoide (mra)
AR086972A1 (es) Procesos para preparar compuestos heterociclicos, que incluyen trans-7-oxo-6-(sulfooxi)-1,6-diazabiciclo[3,2,1]octano-2-carboxamida y sales de la misma
AR081075A1 (es) Derivados de imidazo[1,2-c]pirimidina, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos en el tratamiento de enfermedades autoinmunes e inflamatorias.
AR066911A1 (es) Derivados de piperidina / piperazina
AR067327A1 (es) Derivados de piperidina / piperazina
AR079224A1 (es) Compuestos insecticidas basados en derivados de isoxazolina
AR060590A1 (es) Compuestos imidazo
AR066153A1 (es) Derivados de piperidina / piperazina
AR066154A1 (es) Derivados de piperidina / piperazina
AR069364A1 (es) Derivados heterociclicos que modulan la miosina del musculo liso y/o la miosina no muscular y composiciones farmaceuticas que los contienen

Legal Events

Date Code Title Description
FA Abandonment or withdrawal